Phase II Trial of RAD001 in Refractory Colorectal Cancer

Phase 2

Completed

• Conditions: Colorectal Cancer

• Registration Number: NCT00337545
• Lead Sponsor: Swedish Medical Center

Brief Summary

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Detailed Description

Study is completed and closed.

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-06-15
• Study First Submitted QC: 2006-06-15
• Study First Posted: 2006-06-16
• Study Completion: 2007-04
• Status Verified: 2007-10
• Last Update Submitted: 2007-10-05
• Last Update Posted: 2007-10-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
• Measurable disease
• ECOG 0-2

Exclusion Criteria

• CNS disease
• Chemotherapy or radiotherapy < 4 weeks prior
• Active bleeding diathesis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Swedish Cancer Institute; 🇺🇸 Seattle, Washington, United States